New hope for rare anemia: drug combo shows promise
NCT ID NCT04423367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of two drugs, bortezomib and dexamethasone, in 18 adults with acquired pure red cell aplasia whose disease did not improve or came back after first treatment. The goal was to see if the combination could safely control the condition. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bortezomib and dexamethasone
- What this could lead to
- If successful, this combination could offer a new treatment option for people with pure red cell aplasia who did not respond to or relapsed after initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 18 participants and no comparison group, so results may not apply broadly. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED PURE RED CELL APLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regenerative Medicine Center
Tianjin, China
-
The Second Affilated Hospital of Shandong First Medical University
Tai’an, Shandong, China
-
Zhoukou Central Hospital
Zhoukou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.